Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DANTRIUM vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (Ry R1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
FDA approved for the treatment of spasticity in upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, multiple sclerosis),Malignant hyperthermia (acute treatment and prevention),Neuroleptic malignant syndrome (off-label),Ecstasy (MDMA) intoxication (off-label)
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Metabolized in the liver via microsomal enzymes (CYP3A4 and others) to 5-hydroxydantrolene (active metabolite) and other metabolites. Undergoes enterohepatic recirculation.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
~90% bound to albumin.
Approximately 90–95% bound, primarily to albumin.
Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: ~70% (first-pass metabolism reduces from ~90% absorbed).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
No specific guidelines; use with caution in renal impairment due to potential accumulation. Monitor renal function and reduce dose if toxicity occurs.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Contraindicated in active hepatic disease (elevated AST/ALT, hepatitis, cirrhosis). For Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: avoid use.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Spasticity: 0.5 mg/kg/dose twice daily, titrate up to 0.5-2 mg/kg/dose three times daily; maximum 100 mg four times daily for children >5 years. Malignant hyperthermia: IV 1 mg/kg, repeated as needed.
Not established; safety and efficacy not studied in pediatric patients.
Start at lower end of dosing range (25 mg daily), titrate slowly. Increased risk of sedation, muscle weakness, and hepatic toxicity. Monitor liver function frequently.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Hepatotoxicity: Dantrolene can cause fatal hepatitis, especially with long-term use (≥60 days) and at doses >300 mg/day. Liver function must be monitored before and during therapy. Risk is increased in females, patients >35 years, and those on other hepatotoxic medications.
None
Monitor liver function tests (LFTs) before and during therapy; discontinue if hepatic injury suspected.,May cause muscle weakness, impair ability to drive or operate machinery.,Caution in patients with compromised respiratory function or impaired cardiac function due to negative inotropic effects.,Photosensitivity reactions possible.,Risk of pleural effusion and pericarditis with long-term use.,Use with caution in renal impairment (no dosage adjustment needed, but monitor).
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Active hepatic disease (e.g., hepatitis, cirrhosis),Patients in whom muscle weakness is undesirable (e.g., myasthenia gravis, amyotrophic lateral sclerosis),Hypersensitivity to dantrolene or any component of the formulation,Breastfeeding (discontinue or do not breastfeed; potential for serious adverse reactions in infants)
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
No specific food interactions are established. Avoid alcohol due to additive CNS depression.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
Dantrolene (Dantrium) is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and delayed ossification at doses ≥ 30 mg/kg/day in rats and 45 mg/kg/day in rabbits. There are no adequate and well-controlled studies in pregnant women. Potential risks include skeletal anomalies and embryotoxicity. Use only if potential benefit justifies potential risk to fetus.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Dantrolene is excreted in breast milk at low levels; M/P ratio is approximately 0.5 based on limited data. Theoretical risk of muscle weakness and CNS effects in nursing infants. Caution advised; monitor infant for sedation, hypotonia, or feeding difficulties. Consider alternative therapy if possible.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No specific pharmacokinetic studies in pregnancy; use lowest effective dose. Consider increased clearance due to pregnancy-induced changes; monitor clinical response and adjust as needed. Avoid intravenous administration during labor due to risk of uterine atony.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Monitor liver function tests before and during therapy; hepatotoxicity risk increases with doses >300 mg/day. Do not use in patients with pre-existing hepatic disease. Abrupt discontinuation may precipitate hyperthermia and spasticity rebound. Use with caution in patients with impaired pulmonary function due to potential respiratory muscle weakness.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Report signs of liver problems: yellow skin/eyes, dark urine, abdominal pain, unusual fatigue.,Do not stop taking suddenly; dose must be tapered to avoid withdrawal symptoms.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other CNS depressants while taking this medication.,Use sun protection as photosensitivity may occur.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DANTRIUM vs CHLORZOXAZONE, answered by our medical review team.
DANTRIUM is a Skeletal Muscle Relaxant that works by Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (Ry R1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DANTRIUM and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DANTRIUM is: Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DANTRIUM and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DANTRIUM is classified as Category C. Dantrolene (Dantrium) is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and delayed ossification at doses ≥ 30 mg/kg/. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.